PDCD1 and non-small cell lung carcinoma: This is supported by a recent clinical study (NCT02523469) in which 91% of PD-1 treatment-resistant metastatic NSCLC patients achieved disease control, with 27% partial responses and 64% stable disease after concurrent treatment with N-803 and the αPD-1 antibody nivolumab [23].